News Release

Research Article Cites Cleanascite™ for Purification of Lysyl oxidase (LOX)

MONMOUTH JUNCTION, NJ, October 17, 2023 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their lipid binding technology for purifying and analyzing Lysyl oxidase (LOX) from bovine aorta.

The citation is:

Yao, Yimin, et al. "Accurate quantification of lysyl oxidase concentration in human tissue." bioRxiv (2023): 2023-07.

The family of Lysyl oxidase enzymes play fundamental roles in the formation of the extracellular matrix, through catalyzing the crosslinking of collagen and elastin fibers. Lysyl oxidase (LOX) — one of the 5 family members (LOX, LOXL1-4), is a disease biomarker, with blood concentration positively correlating with progression of fibrosis or cancer. An accurate quantification of LOX concentration can support diagnosis, monitoring of disease progression or treatment success. However, reported LOX concentrations in human blood are inconsistent. Therefore, a novel, high-throughput and sensitive digital enzyme-linked immunosorbent assay was developed using two validated and selective human anti-LOX antibodies and single molecule array technology. Both, the 56 kDa pro-form and the 32 kDa active form can be accurately measured from recombinant and native protein. For Bovine aorta LOX extraction, the article states “30 g of tissue was pulverized in liquid nitrogen and resuspended in cold wash buffer … The mixture was homogenized (T25 IKA Turrax) for 2 minutes on ice then washed thrice with same volumes of ice-cold wash buffer. Between each wash, samples were briefly homogenized and centrifuged at 4500 g for 20 minutes at 4°C and supernatant discarded. The pellet was resuspended and kept in extraction buffer containing 6 M urea, 50 mM sodium borate, pH 8.2 … The mixture was then centrifuged at 10,000 g for 20 minutes at 4°C. The supernatant was further purified by incubating with 0.1 g/mL hydroxyapatite (Sigma-Aldrich, 21223) and Cleanascite (10% w/w, Biotech Support Group) for 30 minutes at 4°C, then centrifuged at 10,000 g for 20 minutes at 4°C. The supernatant was then concentrated, buffer exchanged with 10 kDa Amicon filters … and portion containing the 32 kDa LOX was collected. The presence of LOX was verified by means of Western Blot.” This study demonstrates the validation and use of a sensitive and accurate method for measuring LOX concentration in human samples.

“It is great to see yet another completely different use of Cleanascite™. Here it is employed to efficiently clear lipids from an aorta tissue lysate, to help in the purification and analysis of Lysyl oxidase (LOX).” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords

Lysyl oxidase (LOX), lipid clarification, Cleanascite™.

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance and family specific proteome enrichment. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com